Mounjaro Pulls In $10.7B in Q3 as Lilly's Growth Engine Keeps Humming
LLY sits 62% above its 52-week low of $809.63.
Summary
Mounjaro generated $10.7B in third-quarter revenue, a fresh data point on Lilly's biggest growth driver now that the full results are in. Total third-quarter revenue came to $24.4B, with U.S. revenue up 34% to $15.1B as U.S. volume rose 41% and realized prices fell 7%. Adjusted EPS was $7.48 and net income was $6.45B. The quarter lands against a steep base: Q2 revenue jumped 48% to $23B on Mounjaro and Zepbound, and management now guides full-year revenue to $91B-$92B, up from the $85B-$87B range set in August. A $10.7B quarter for a single drug keeps that guidance range in reach and extends the run of outsized beats that have pushed the stock near its 52-week high, while the rest of the quarter's P&L includes Zepbound and the newly approved oral obesity drug Foundayo.
At the time of this announcement, LLY was trading at $1,315.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2T. The 52-week trading range was $809.63 to $1,321.21. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.